Related Experiment Video
Updated: Jan 31, 2026

In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model
Published on: November 28, 2017
Cancer peptide vaccine targeted glypican-3 antigen
Abstract:
We identified glypican-3 (GPC3) as a carcinoembryonic antigen would be an ideal target for hepatocellular carcinoma (HCC) immunotherapy. We identified HLA-A24- and A2-restricted GPC3-derived peptides that can induce GPC3-reactive CTLs but not autoimmunity. In a phase I using this peptide vaccine in patients with advanced HCC, we collected evidence of immune responses, antitumor effects, and the safety. We could detect peptide-specific CTLs in the peripheral blood of most patients, and established a lot of peptide-specific CTL clones from PBMCs and tumor of patients vaccinated. In a phase II as an adjuvant therapy for HCC patients, it improved the 1-y recurrence rate in patients with GPC3-positive tumors. GPC3 is overexpressed in ovarian clear cell carcinoma, hepatoblastoma, and so on. GPC3 peptide vac- cine or GPC3 peptide specific TCR-T cell therapy has hope for treatment or prevention of these GPC3-positive cancers.
More Related Videos
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Peptide Bonds
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3

